Resveratrol and SRT1720, both of which are Sirt1 activators, ameliorate fatty liver with reduced lipid synthesis and increased rates of fatty acid oxidation through Sirt1 and adenosine monophosphate-activated protein kinase (AMPK) activation [11]. The gene discussed is SIRT1; the disease is Hepatic steatosis.